NeoGenomics Inc
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing se… Read more
NeoGenomics Inc - Asset Resilience Ratio
NeoGenomics Inc (NEO) has an Asset Resilience Ratio of 0.00% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2024)
This chart shows how NeoGenomics Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down NeoGenomics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: NeoGenomics Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
NeoGenomics Inc Industry Peers by Asset Resilience Ratio
Compare NeoGenomics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF |
Diagnostics & Research | 1.12% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
NSN Co. Ltd
KQ:031860 |
Diagnostics & Research | 1.72% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
Annual Asset Resilience Ratio for NeoGenomics Inc (2009–2024)
The table below shows the annual Asset Resilience Ratio data for NeoGenomics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 1.21% | $19.83 Million | $1.64 Billion | -3.11pp |
| 2023-12-31 | 4.33% | $72.72 Million | $1.68 Billion | -5.72pp |
| 2022-12-31 | 10.05% | $174.81 Million | $1.74 Billion | -0.57pp |
| 2021-12-31 | 10.62% | $198.56 Million | $1.87 Billion | +3.79pp |
| 2020-12-31 | 6.83% | $67.55 Million | $988.33 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $343.34 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $337.12 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $367.95 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $81.11 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $39.92 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $30.07 Million | -- |
| 2011-12-31 | 2.51% | $500.00K | $19.95 Million | -1.16pp |
| 2010-12-31 | 3.66% | $500.00K | $13.65 Million | -4.06pp |
| 2009-12-31 | 7.72% | $1.00 Million | $12.95 Million | -- |